AVIGI Therapeutics develops first‑in‑class covalent inhibitors of heparanase, a key enzyme in extracellular matrix remodeling, with lead candidate VL166 in preclinical development across several solid and hematologic cancers. Founded in 2024 in Leiden, the company also explores heparanase inhibition in inflammatory, fibrotic, diabetic and cardiovascular indications and has raised over €383k in early funding.